ArticleTropical diseases, travel medicine and vaccines2026
Rwanda's National Reference Laboratory Operational Capacity during the 2024 Marburg Virus Disease Outbreak Response.
Article in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRwanda reported its first Marburg virus disease (MVD) outbreak in September 2024. This study presents an assessment of Rwanda's National Reference Laboratory Operational Capacity during the 2024 Marburg Virus Disease Outbreak Response.
methodsThe assessment was conducted using the World Health Organization laboratory assessment tool for viral haemorrhagic fever (VHF) diagnostic capacity. This was complemented by an evaluation of various laboratory quality indicators like the turnaround time (TAT). Data were collected through direct observation, documents' review, and interviews with laboratory staff. Descriptive analysis of key response activities and observations was conducted using Microsoft Office (Excel). Also, the map of testing sites was drawn using QGIS 3.40.0 software.
resultsThe NRL's response to the MVD outbreak achieved an overall score of 98%. All components scored 100% except for the quality of the laboratory system, which scored 89% due to the lack of External Quality Assessment (EQA) for MVD. Key achievements during the outbreak response included (i) reduction in the turnaround time (TAT) from sample reception to releasing results from 24 to 7 h, (ii) the recruitment of more laboratory staff supporting sample collection, transportation, testing and results reporting, (ii) creation of five new MVD testing sites, (iii) training of laboratory staff, (iv) digitalization of the laboratory flow, and (v) establishing a 24/7 telephone line for easy communication with laboratories on MVD suspected samples being processed.
conclusionThe strong performance of the NRL highlights its robust laboratory system, which allowed effective testing of MVD suspected cases. We recommend implementing an EQA scheme for VHF diagnostics in Rwanda, including the MVD. Also, improving measures for biosafety, biosecurity, and infection prevention and control in all health facilities would reduce the risk of such infections in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.